Any feedback?
Literature summary for 1.3.1.1 extracted from
- The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil (2009), Pathol. Biol., 57, 470-476.
Application
| Application | Comment | Organism |
|---|---|---|
| analysis | high performance liquid chromatography method for quantification of dihydrouracil to uracil ratio in plasma and application in screening for dihydropyrimidine dehydrogenase deficiency in patients treated with 5-fluorouracil. Plasma dihydrouracil to uracil ratio values are highly correlated with the plasma 5-fluorouracil-half-life values and are significantly associated with the toxic side effects, whereas, data set provided from genetic analysis of the coding sequences of the DPD gene are found to be insufficient to explain all the cases of the 5-fluorouracil-related toxicity pattern. Assay is suitable for routine clinical use for dihydropyrimidine dehydrogenase deficiency assessment in patients prior to 5-fluorouracil administration | Homo sapiens |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Homo sapiens | - |
colorectal cancer patients treated with 5-fluorouracil | - |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
